Compare IDEXX Laboratories, Inc. (IDXX) vs Ralph Lauren Corp (RL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs Ralph Lauren Corp — how do they compare? IDEXX Laboratories, Inc. trades at $563.81 (market cap $44.48B), while Ralph Lauren Corp trades at $375.67 (market cap $22.41B). The key difference: IDEXX Laboratories, Inc. is the larger of the two by market cap, and Ralph Lauren Corp pays a 0.99% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals.
| IDXX | RL | |
|---|---|---|
Market Cap | $44.48B | $22.41B |
Sector | Health | Consumer Cyclical |
52-Week High | $766.68 | $414.25 |
52-Week Low | $520.87 | $283.34 |
Enterprise Value | $45.38B | $23.35B |
Dividend Yield | — | 0.99% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories trades at $552.46, down 2.64% today, with neutral technical signals but strong fundamental performance. The company maintains robust profitability with 24.63% net margins and has beaten earnings expectations for three consecutive quarters. Recent news highlights AI integration in medical devices and upcoming Q2 2026 results on August 4, 2026. The stock shows consistent revenue growth from $3.4B in 2022 to $4.3B in 2025.
Outlook remains positive given earnings momentum and analyst consensus, though elevated valuation ratios (P/E 41.49) pose risks. Key catalysts include Q2 earnings release and continued AI adoption in veterinary diagnostics. Primary risks involve competitive pressures and market volatility affecting premium valuations.
Ralph Lauren (RL) trades at $382.93, up 0.65% today, with strong fundamentals including 11.6% net margin and 34.66% ROE. Recent earnings beats and a $1.00 dividend signal financial health, though technical indicators show bearish momentum near resistance at $383. Revenue growth to $7.08B in 2025 and a $445.71 analyst target suggest upside potential.
The stock offers growth through premium branding and digital expansion, but faces risks from consumer discretionary weakness and high valuation multiples. Analyst consensus is strongly bullish (66% buy ratings), yet technical pressure and macroeconomic sensitivity warrant caution for near-term entry points.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About Ralph Lauren Corp
Founded by designer Ralph Lauren in 1967, Ralph Lauren Corp. designs, markets, and distributes lifestyle products in North America, Europe, and Asia. Its products include apparel, footwear, eyewear, jewelry, leather goods, home products, and fragrances. The company's brands include Ralph Lauren Collection, Polo Ralph Lauren, Lauren Ralph Lauren, and Double RL. Distribution channels for Ralph Lauren include wholesale (including department stores and specialty stores), retail (including company-owned retail stores and e-commerce), and licensing.
Read more on RL →
